#EAACICongress2026
LightNews LightNews
nejm.org
In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. Full HAELO trial results: https://nej.md/4gaSsbi

#EAACICongress2026
A graph from the article "Lonvogran Zicluemeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema" published in the New England Journal of Medicine, dated June 11, 2026. The trial name, HAELO, is in parentheses next to the article title. A graph the mean number of angioedema attacks per month between "Placebo" and "Lonvoz-2" groups over time.
June 13, 2026 at 6:25 AM